A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: Comparative viremia and immunogenicity

Srilatha Edupuganti, Rachel B. Eidex, Harry Keyserling, Rama S. Akondy, Robert Lanciotti, Walter Orenstein, Carlos Del Rio, Yi Pan, Troy Querec, Harvey Lipman, Alan Barrett, Rafi Ahmed, Dirk Teuwen, Martin Cetron, Mark J. Mulligan

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We evaluated whether coadministration of the yellow fever (YF) virus vaccine with human immunoglobulin (Ig) that contained YF virus-neutralizing antibodies would reduce post-vaccination viremia without compromising immunogenicity and thus, potentially mitigate YF vaccine-associated adverse events. We randomized 80 participants to receive either YF vaccine and Ig or YF vaccine and saline placebo. Participants were followed for 91 days for safety and assessments of viremia and immunogenicity. There were no differences found between the two groups in the proportion of vaccinated participants who developed viremia, seroconversion, cluster of differentiation (CD)-8+ and CD4+ T-cell responses, and cytokine responses. These results argue against one putative explanation for the increased reporting of YF vaccine side effects in recent years (i.e., a change in travel clinic practice after 1996 when hepatitis A prophylaxis with vaccine replaced routine use of pre-travel Ig, thus potentially removing an incidental YF vaccineattenuating effect of anti-YF virus antibodies present in Ig) (Clinical Trials.gov identifier: NCT00254826).

Original languageEnglish (US)
Pages (from-to)172-177
Number of pages6
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume88
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Yellow Fever Vaccine
Yellow fever virus
Viremia
Immunoglobulins
Placebos
Yellow Fever
Hepatitis A
Neutralizing Antibodies
Vaccination
Vaccines
Clinical Trials
Cytokines
T-Lymphocytes
Safety
Antibodies

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Virology

Cite this

A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo : Comparative viremia and immunogenicity. / Edupuganti, Srilatha; Eidex, Rachel B.; Keyserling, Harry; Akondy, Rama S.; Lanciotti, Robert; Orenstein, Walter; Del Rio, Carlos; Pan, Yi; Querec, Troy; Lipman, Harvey; Barrett, Alan; Ahmed, Rafi; Teuwen, Dirk; Cetron, Martin; Mulligan, Mark J.

In: American Journal of Tropical Medicine and Hygiene, Vol. 88, No. 1, 01.2013, p. 172-177.

Research output: Contribution to journalArticle

Edupuganti, S, Eidex, RB, Keyserling, H, Akondy, RS, Lanciotti, R, Orenstein, W, Del Rio, C, Pan, Y, Querec, T, Lipman, H, Barrett, A, Ahmed, R, Teuwen, D, Cetron, M & Mulligan, MJ 2013, 'A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: Comparative viremia and immunogenicity', American Journal of Tropical Medicine and Hygiene, vol. 88, no. 1, pp. 172-177. https://doi.org/10.4269/ajtmh.2012.12-0179
Edupuganti, Srilatha ; Eidex, Rachel B. ; Keyserling, Harry ; Akondy, Rama S. ; Lanciotti, Robert ; Orenstein, Walter ; Del Rio, Carlos ; Pan, Yi ; Querec, Troy ; Lipman, Harvey ; Barrett, Alan ; Ahmed, Rafi ; Teuwen, Dirk ; Cetron, Martin ; Mulligan, Mark J. / A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo : Comparative viremia and immunogenicity. In: American Journal of Tropical Medicine and Hygiene. 2013 ; Vol. 88, No. 1. pp. 172-177.
@article{1c1bb0860d624f6e8fae8fdaa2293eff,
title = "A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: Comparative viremia and immunogenicity",
abstract = "We evaluated whether coadministration of the yellow fever (YF) virus vaccine with human immunoglobulin (Ig) that contained YF virus-neutralizing antibodies would reduce post-vaccination viremia without compromising immunogenicity and thus, potentially mitigate YF vaccine-associated adverse events. We randomized 80 participants to receive either YF vaccine and Ig or YF vaccine and saline placebo. Participants were followed for 91 days for safety and assessments of viremia and immunogenicity. There were no differences found between the two groups in the proportion of vaccinated participants who developed viremia, seroconversion, cluster of differentiation (CD)-8+ and CD4+ T-cell responses, and cytokine responses. These results argue against one putative explanation for the increased reporting of YF vaccine side effects in recent years (i.e., a change in travel clinic practice after 1996 when hepatitis A prophylaxis with vaccine replaced routine use of pre-travel Ig, thus potentially removing an incidental YF vaccineattenuating effect of anti-YF virus antibodies present in Ig) (Clinical Trials.gov identifier: NCT00254826).",
author = "Srilatha Edupuganti and Eidex, {Rachel B.} and Harry Keyserling and Akondy, {Rama S.} and Robert Lanciotti and Walter Orenstein and {Del Rio}, Carlos and Yi Pan and Troy Querec and Harvey Lipman and Alan Barrett and Rafi Ahmed and Dirk Teuwen and Martin Cetron and Mulligan, {Mark J.}",
year = "2013",
month = "1",
doi = "10.4269/ajtmh.2012.12-0179",
language = "English (US)",
volume = "88",
pages = "172--177",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "1",

}

TY - JOUR

T1 - A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo

T2 - Comparative viremia and immunogenicity

AU - Edupuganti, Srilatha

AU - Eidex, Rachel B.

AU - Keyserling, Harry

AU - Akondy, Rama S.

AU - Lanciotti, Robert

AU - Orenstein, Walter

AU - Del Rio, Carlos

AU - Pan, Yi

AU - Querec, Troy

AU - Lipman, Harvey

AU - Barrett, Alan

AU - Ahmed, Rafi

AU - Teuwen, Dirk

AU - Cetron, Martin

AU - Mulligan, Mark J.

PY - 2013/1

Y1 - 2013/1

N2 - We evaluated whether coadministration of the yellow fever (YF) virus vaccine with human immunoglobulin (Ig) that contained YF virus-neutralizing antibodies would reduce post-vaccination viremia without compromising immunogenicity and thus, potentially mitigate YF vaccine-associated adverse events. We randomized 80 participants to receive either YF vaccine and Ig or YF vaccine and saline placebo. Participants were followed for 91 days for safety and assessments of viremia and immunogenicity. There were no differences found between the two groups in the proportion of vaccinated participants who developed viremia, seroconversion, cluster of differentiation (CD)-8+ and CD4+ T-cell responses, and cytokine responses. These results argue against one putative explanation for the increased reporting of YF vaccine side effects in recent years (i.e., a change in travel clinic practice after 1996 when hepatitis A prophylaxis with vaccine replaced routine use of pre-travel Ig, thus potentially removing an incidental YF vaccineattenuating effect of anti-YF virus antibodies present in Ig) (Clinical Trials.gov identifier: NCT00254826).

AB - We evaluated whether coadministration of the yellow fever (YF) virus vaccine with human immunoglobulin (Ig) that contained YF virus-neutralizing antibodies would reduce post-vaccination viremia without compromising immunogenicity and thus, potentially mitigate YF vaccine-associated adverse events. We randomized 80 participants to receive either YF vaccine and Ig or YF vaccine and saline placebo. Participants were followed for 91 days for safety and assessments of viremia and immunogenicity. There were no differences found between the two groups in the proportion of vaccinated participants who developed viremia, seroconversion, cluster of differentiation (CD)-8+ and CD4+ T-cell responses, and cytokine responses. These results argue against one putative explanation for the increased reporting of YF vaccine side effects in recent years (i.e., a change in travel clinic practice after 1996 when hepatitis A prophylaxis with vaccine replaced routine use of pre-travel Ig, thus potentially removing an incidental YF vaccineattenuating effect of anti-YF virus antibodies present in Ig) (Clinical Trials.gov identifier: NCT00254826).

UR - http://www.scopus.com/inward/record.url?scp=84872312208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872312208&partnerID=8YFLogxK

U2 - 10.4269/ajtmh.2012.12-0179

DO - 10.4269/ajtmh.2012.12-0179

M3 - Article

C2 - 23208880

AN - SCOPUS:84872312208

VL - 88

SP - 172

EP - 177

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 1

ER -